Gland Pharma Ltd. (GLAND) AI Stock Analysis

• Market Cap: ₹321.71B
• Dividend Yield: 0.92%
• Average Volume (3M): 7.12K
• Price to Earnings (P/E): 41.8
• Beta (1Y): 0.52
• Revenue Growth: -2.34%
• EPS Growth: 6.64%
• Country: IN
• Employees: 4,217
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - General
• EPS (TTM): 13.08
• Shares Outstanding: 164,756,420
• 10 Day Avg. Volume: 10,764
• 30 Day Avg. Volume: 7,116
• PEG Ratio: -3.82
• Price to Book (P/B): 2.80
• Price to Sales (P/S): 4.56
• P/FCF Ratio: 48.27
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹1,886.00
• Price Target Upside: -2.76% Downside
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 7

• Rating: 69 Neutral
• Price Target: ₹2,102.00 ▲(8.38% Upside)

Gland Pharma Ltd. shows strong financial performance with consistent growth and a robust balance sheet, which is the most significant factor in its overall score. Technical analysis indicates a stable trend but with bearish momentum, while valuation metrics suggest the stock is relatively expensive. The absence of earnings call data and corporate events limits further insights.

Gland Pharma Ltd. Business Overview & Revenue Model

Company Description

Gland Pharma Limited engages in the development, manufacture, and marketing of injectable-focused generic liquid parenteral products. The company's primary molecules include heparin sodium, enoxaparin sodium, rocuronium bromide, and daptomycin injections, as well as others. It offers its products under various therapeutic categories, such as anti-infectives, anesthetics, anti-coagulants and their antidotes, anti-malarial, cardiology, gastro-intestinal, pain management, hormones and related drugs, fertility supplements, Gnrh agonists and antagonists, anti-neoplastic, gynecological, neurological and central nervous system, respiratory, blood related, ophthalmological and otological, pain/analgesics, orthopedics, hematinic, vitamins/minerals/nutrients, and others. The company also provides contract development services. It sells its products primarily under a business to business in the United States, Europe, Canada, Australia, India, and internationally. The company was incorporated in 1978 and is based in Hyderabad, India. Gland Pharma Limited is a subsidiary of Fosun Pharma Industrial Pte. Ltd.

How the Company Makes Money

Gland Pharma Ltd. generates revenue primarily through the manufacturing and sale of injectable pharmaceutical products. The company serves a diverse clientele, including hospitals, clinics, and pharmaceutical companies around the world. A significant portion of its income is derived from export sales to highly regulated markets like the United States, Europe, Canada, and Australia, where it supplies both generic injectables and contract manufacturing services. Additionally, the company partners with other pharmaceutical companies for co-development and out-licensing agreements, further enhancing its revenue streams. Its earnings are bolstered by its focus on producing complex and high-value products, which allows it to maintain competitive pricing and secure long-term contracts.

Gland Pharma Ltd. Financial Statement Overview

Summary

Gland Pharma Ltd. exhibits strong financial health with consistent revenue growth, solid profitability metrics, and a strong balance sheet. The company maintains efficient cash flow management, although recent declines in net income and free cash flow growth require careful attention.

Income Statement

Gland Pharma Ltd. has shown consistent revenue growth over the years, although there was a slight dip in 2025. The company maintains strong gross and net profit margins, with EBIT and EBITDA margins indicating efficient operational management. However, the recent decline in net income may point to potential challenges in maintaining profit margins.

Balance Sheet

The company demonstrates a robust balance sheet with a strong equity base and a low debt-to-equity ratio, indicating low financial leverage and risk. The equity ratio is solid, reflecting financial stability and a healthy capital structure. However, the slight increase in total liabilities over the years requires monitoring.

Cash Flow

Operating cash flow remains strong, supporting the company's ability to fund operations. The free cash flow is positive, though it has shown some fluctuations. The cash flow ratios suggest efficient cash management, yet the decrease in free cash flow growth rate in recent years could indicate challenges in cash generation.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	57.20B	56.17B	56.42B	35.92B	43.84B	34.24B
Gross Profit	31.52B	33.27B	30.88B	19.39B	22.75B	19.32B
EBITDA	15.47B	12.69B	15.03B	12.09B	17.34B	14.37B
Net Income	7.70B	6.99B	7.72B	7.81B	12.12B	9.97B
Balance Sheet
Total Assets	0.00	112.25B	106.61B	87.78B	78.34B	64.96B
Cash, Cash Equivalents and Short-Term Investments	29.52B	29.52B	19.39B	37.63B	32.43B	30.03B
Total Debt	0.00	3.14B	3.72B	44.53M	47.43M	49.95M
Total Liabilities	-91.51B	20.74B	19.37B	8.19B	6.76B	5.93B
Stockholders Equity	91.51B	91.51B	87.24B	79.59B	71.58B	59.03B
Cash Flow
Free Cash Flow	0.00	5.30B	6.07B	1.41B	2.69B	3.76B
Operating Cash Flow	0.00	9.15B	9.97B	3.64B	7.91B	6.05B
Investing Cash Flow	0.00	17.05B	-17.57B	12.08B	-10.03B	-15.24B
Financing Cash Flow	0.00	-4.33B	-7.99B	149.19M	348.98M	12.38B

Gland Pharma Ltd. Technical Analysis

• Technical Analysis Sentiment: Neutral
• Last Price: 1939.50
• 50DMA: Negative
• 100DMA: Positive
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:GLAND, the sentiment is Neutral. The current price of 1939.5 is below the 20-day moving average (MA) of 1978.15, below the 50-day MA of 1958.68, and above the 200-day MA of 1700.10, indicating a neutral trend. The MACD of 8.54 indicates Positive momentum. The RSI at 45.26 is Neutral, neither overbought nor oversold. The STOCH value of 38.87 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for IN:GLAND.

Gland Pharma Ltd. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
AUROPHARMA	76 Outperform	₹635.16B	18.73	―	0.36%	7.76%	-2.84%
DRREDDY	74 Outperform	₹1.04T	18.32	―	0.64%	15.86%	2.02%
TORNTPHARM	72 Outperform	₹1.19T	59.40	―	0.91%	7.63%	15.39%
GLAND	69 Neutral	₹321.71B	41.77	―	0.92%	-2.34%	6.64%
SUNPHARMA	69 Neutral	₹3.92T	37.80	―	0.97%	9.28%	-0.17%
GLAXO	66 Neutral	₹463.45B	48.76	―	1.97%	6.65%	48.47%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%

Gland Pharma Ltd. Corporate Events

Gland Pharma Appoints New Secretarial Auditors to Strengthen Governance

Gland Pharma Limited has announced the appointment of M/s. RVR & Associates as the Secretarial Auditors for a term of five years, following approval at the company’s 47th Annual General Meeting. This strategic appointment is expected to enhance the company’s compliance management and corporate governance, potentially strengthening its market position and stakeholder confidence.